Israel’s Teva is launching Truxima, a biosimilar for Rituxan – Roche’s oncology treatment. It is initially targeted at non-Hodgkin’s Lymphoma patients but also could treat rheumatoid arthritis and other conditions.
https://www.calcalistech.com/ctech/articles/0,7340,L-3773475,00.html